Other formats:
BibTeX
LaTeX
RIS
@article{992802,
author = {Szturz, Petr and Adam, Zdeněk and Chovancová, Jana and Stehlíková, Olga and Klabusay, Martin and Řehák, Z. and Koukalová, R. and Zahradová, Lenka and Krejčí, Marta and Pour, Luděk and Hájek, Roman and Mayer, Jiří},
article_location = {LONDON},
article_number = {10},
doi = {http://dx.doi.org/10.3109/10428194.2011.621564},
keywords = {Lenalidomide; Castleman disease},
language = {eng},
issn = {1042-8194},
journal = {Leukemia & Lymphoma},
title = {Lenalidomide: a new treatment option for Castleman disease},
volume = {53},
year = {2012}
}
TY - JOUR
ID - 992802
AU - Szturz, Petr - Adam, Zdeněk - Chovancová, Jana - Stehlíková, Olga - Klabusay, Martin - Řehák, Z. - Koukalová, R. - Zahradová, Lenka - Krejčí, Marta - Pour, Luděk - Hájek, Roman - Mayer, Jiří
PY - 2012
TI - Lenalidomide: a new treatment option for Castleman disease
JF - Leukemia & Lymphoma
VL - 53
IS - 10
SP - 2089-2091
EP - 2089-2091
PB - INFORMA HEALTHCARE
SN - 10428194
KW - Lenalidomide
KW - Castleman disease
N2 - A male born in 1961, aged 46, was referred to our department for evaluation of splenomegaly and generalized lymphadenopathy aff ecting the cervical, axillary, mediastinal, retroperitoneal and inguinal regions. Laboratory data revealed an increased erythrocyte sedimentation rate (16 mm/h and 30 mm/2 h) and C-reactive protein level (35.4 mg/L). Total protein and full blood counts as well as renal and hepatic profi les were within normal ranges, and microbiological screening revealed no infectious etiology. Other fi ndings, including radiological examinations and bone marrow biopsy, showed no further pathologies. Th e patient ’ s other medical history was signifi cant for arterial hypertension, chronic infl ammatory demyelinating polyneuropathy and mild right hemi-paresis with expressive language disorder. Based on lymph node biopsies from retroperitoneal and both inguinal regions, the patient was diagnosed with the plasma-cell variant of CD. Th e presence of a large pelvic mass compressing adjacent structures indicated the patient for therapy initiation. During fi rst-line treatment (R-CHOP: rituximab 375 mg/m 2 , cyclophosphamide 750 mg/m 2 , doxorubicin 50 mg/m 2 and vincristine 2 mg intravenously on day 1; prednisone 100 mg perorally on days 1 – 5 in a 21-day cycle, three cycles in total, 12/2008 – 2/2009), clinical progression of the disease was evident (gastrointestinal symptoms, swollen hands and feet with signs of vasculitis), and there was no radiological response on a restaging computed tomography (CT) examination after 3 months.
ER -
SZTURZ, Petr, Zdeněk ADAM, Jana CHOVANCOVÁ, Olga STEHLÍKOVÁ, Martin KLABUSAY, Z. ŘEHÁK, R. KOUKALOVÁ, Lenka ZAHRADOVÁ, Marta KREJČÍ, Luděk POUR, Roman HÁJEK and Jiří MAYER. Lenalidomide: a new treatment option for Castleman disease. \textit{Leukemia \&{} Lymphoma}. LONDON: INFORMA HEALTHCARE, 2012, vol.~53, No~10, p.~2089-2091. ISSN~1042-8194. doi:10.3109/10428194.2011.621564.
|
